HeberFERON®, therapeutic alternative for non-melanoma skin cancer in primary care
Abstract
Introduction: Non-melanoma skin cancer is, in a sustained manner, the first cause of morbidity due to malignant tumors in Cuba. HeberFERON® is applied as a therapeutic modality with favorable experiences in this disease.
Objective: To evaluate the clinical effectiveness of HeberFERON® in non-melanoma skin cancer.
Methods: An observational, descriptive and prospective study was conducted between January 1st, 2017 and December 2023, at the Teaching Polyclinic Dr. Carlos J. Finlay, in the municipality of Colón, province of Matanzas. It included 176 patients and 201 lesions. The dose was 10.5 million international units, three times a week, for three weeks, perilesional and intradermal. The variables were age, sex, phototype, number of tumors, tumor profile, location, tumor type, evolution time, diameter, cancer variants, subtypes and histological differentiation. Four response categories were considered: complete, partial, stable and progressive disease. The objective response (complete plus partial) was included. A clinical record was prepared. The SPSS package was used for statistical processing and ethical principles were met.
Results: Male sex, phototype II, and patients with single lesions predominated. Primary tumors and head-face-neck location predominated. In the tumor with the highest incidence, lesions of 20 mm or less predominated. In the other neoplastic variant, the lesions frequently exceed 20 mm. The objective response in both tumors exceeded the effectiveness indicator, although basal cell carcinoma experienced better responses.
Conclusions: The mixture of interferons was effective in both variants of non-melanoma skin cancer.
Downloads
References
Ministerio de Salud Pública. Prevención, diagnóstico y tratamiento del cáncer de piel [Internet]. La Habana: Editorial Ciencias Médicas; 2023 [citado 02/02/2024]. Disponible en: http://www.ecimed.sld.cu/2023/08/02/prevencion-diagnostico-y-tratamiento-del-cancer-de-piel/
Nanz L, Keim U, Katalinic A, et al. Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. Cancers [Internet]. 2024 [citado 02/02/2024];16:606. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10854623/pdf/cancers-16-00606.pdf
Do Nascimento MI, Furtado Cardoso de Moraes JR, Costa Silva ER, et al. Trends in non-Melanoma Skin Cancer Mortality in Brazil and its Macroregions. Rev bras cancerol [Internet]. 2022 [citado 02/11/2023];68(1):e022083. Disponible en: http://docs.bvsalud.org/biblioref/2022/06/1370993/sfreireart2_publicado.pdf
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistic 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 [citado 02/11/2023];71(3):209-49. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33538338/
Dirección de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud 2022 [Internet]. La Habana: Ministerio de Salud Pública; 2023 [citado 02/02/2024]. Disponible en: http://salud.msp.gob.cu/wp-content/Anuario/Anuario-2022.pdf
Gómez-Arias PJ, Arias-Blanco MC, Redondo-Sánchez J, et al. Utilidad y eficiencia de la teledermatoscopia en el manejo del cáncer de piel en atención primaria. SEMERGEN [Internet]. 2020 [citado 02/02/2024];46(8):553-9. Disponible en: https://pesquisa.bvsalud.org/portal/resource/midias/ibc-201355
Alonso-Belmonte C, Montero-Vilchez T, Arias-Santiago S, et al. Situación actual de la prevención del cáncer de piel: una revisión sistemática. Actas Dermosifiliogr [Internet]. 2022 [citado 02/02/2024];113(8):781-91 Disponible en: https://www.actasdermo.org/es-situacion-actual-prevencion-del-cancer-articulo-S0001731022003386
Schmults CD, Blitzblau R, Aasi SZ, et al. NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022. J Natl Compr Canc Netw [Internet]. 2021 [citado 02/02/2024];9(12):1382-94. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34902824/
Schmults CD, Blitzblau R, Aasi SZ, et al. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw [Internet]. 2023 [citado 02/02/2024];21(11):1181-203. Disponible en: http://pubmed.ncbi.nlm.nih.gov/37935106/
Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer [Internet]. 2019 [citado 20/02/2024];118:10-34. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31288208/
Vílchez-Márquez F, Borregón-Nofuentes P, Barchino-Ortíz L, et al. Carcinoma basocelular cutáneo: diagnóstico y tratamiento en atención especializada dermatológica. Guía de Práctica Clínica de la AEDV. Actas Dermosifiliogr [Internet]. 2020 [citado 20/02/2024];111(4):291-9 Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0001731020300016
CECMED. HEBERFERON® (Interferón alfa 2b hu-rec + Interferón gamma hu-rec) [Internet]. La Habana: Ministerio de Salud Pública; 2022 [citado 20/02/2024]. Disponible en: https://www.cecmed.cu/registro/rcp/biologicos/heberferonr-interferon-alfa-2b-hu-rec-interferon-gamma-hu-rec?fbclid=IwAR311qZInNQ1L6vEbgaWUiHr-_404Pih16o08-KSnXCh5ax3zbqpC06n6vk
López-Pupo N, Manganelly-Fonseca Y, Tablada-Robinet ME, et al. Utilidad del HeberFERON en pacientes con carcinoma basocelular. MEDISAN [Internet]. 2021 [citado 23/04/2024];25(6). Disponible en: http://medisan.sld.cu/index.php/san/article/view/3867/html
Del-Río-Ysla MB, Abreu-Rivero Y, Matos-Pelegrin Y, et al. Resultado terapéutico del uso del HeberFERON en pacientes con carcinoma basocelular. MediCiego [Internet]. 2020 [citado 23/02/2024];26(4):e2056. Disponible en: http://revmediciego.sld.cu/index.php/mediciego/article/view/2056/3676
Rodríguez-Rosales S, Fonseca-Núñez YD, Fuentes-Gómez L, et al. Efectividad del HeberFERON en el tratamiento del carcinoma basocelular. Multimed [Internet]. 2023 [citado 23/02/2024];27. Disponible en: http://revmultimed.sld.cu/index.php/mtm/article/view/2515
Rodríguez-Fonseca RA, de la Rosa-Santana JD, López-Wilson A, et al. Tratamiento con HeberFERON en pacientes con carcinoma basocelular del Hospital Docente Clínico Quirúrgico “Dr. Miguel Enríquez”, La Habana. Gac Med Est [Internet]. 2020 [citado 02/11/2023];1(2):122-32. Disponible en: https://revgacetaestudiantil.sld.cu/index.php/gme/article/download/26/59/103
Martínez-Suárez C, Roben-Aguilar Y, Reyes-Acosta O, et al. Basal Cell Carcinoma Treated with HeberFERON. A Real-World Retrospective Study. Clin Oncol [Internet]. 2021 [citado 02/11/2023];6:1872. Disponible en: http://www.clinicsinoncology.com/open-access/basal-cell-carcinoma-treated-with-heberferon-a-realnbspworld-8131.pdf
Ferrá-Torres TM, Sánchez-Rodríguez ES, Ballester-Caballero Y, et al. Caracterización de pacientes con carcinoma basocelular tratados con HeberFERON. Arch méd Camagüey [Internet]. 2020 [citado 23/04/2023];24(2):e7136. Disponible en: http://revistaamc.sld.cu/index.php/amc/article/view/7136/3532
Bermúdez-Sañudo D, Monzón-Díaz Y, Piña-Rodríguez Y, et al. Resultados del uso de HeberFERON en pacientes con carcinoma basocelular de alto riesgo en Matanzas. Rev Méd Electrón [Internet]. 2023 [citado 23/02/2024];45(5). Disponible en: http://revmedicaelectronica.sld.cu/index.php/rme/article/view/5124
Flores-López A, Morán-Martínez J, Martínez-Arroyo S, et al. Criterios de Evaluación en Tumores Sólidos 1.1 (RECIST 1.1) en pacientes con cáncer primario y/o metastásico o enfermedad metastásica recurrente. Rev S Científica [Internet]. 2018 [citado 20/02/2024];16(1):8-12. Disponible en: https://www.researchgate.net/publication/332382922_Criterios_de_Evaluacion_en_Tumores_Solidos_11_RECIST_11_en_pacientes_con_Cancer_Primario_yo_Metastasico_o_Enfermedad_Metastasica_Recurrente
Asociación Médica Mundial. Declaración de helsinki de la AMM – principios éticos para las investigaciones médicas con participantes humanos [Internet]. Ferney-Voltaire: Asociación Médica Mundial; 2024 [citado 20/02/2024]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
Ciążyńska M, Kamińska‑Winciorek G, Lange D, et al. The incidence and clinical analysis of non melanoma skin cancer. Sci Rep [Internet]. 2021 [citado 23/04/2024];11:4337 Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900109/pdf/41598_2021_Article_83502.pdf
Gürsel-Ürün Y, Fiçicioğlu S, Can N. Clinical, Dermoscopic and Histopathological Evaluation of Basal Cell Carcinoma Subtypes. Dermatol Pract Concept. 2023;13(1):e2023004. DOI: 10.5826/dpc.1301a4.
Fernández-Martori M, Soler-Cárdenas SF, Amador-García Y, et al. Carcinoma epidermoide de piel tratado con HeberFERON®. Rev Méd Electrón [Internet]. 2022 [citado 19/05/2024];44(2). Disponible en: https://revmedicaelectronica.sld.cu/index.php/rme/article/view/4662
Tejera-Vaquerizo A, Cañueto J, Nagore E. ¿Es la estimación del tiempo de duplicación tumoral posible y útil en el cáncer de piel? Actas Dermosifiliogr [Internet]. 2023 [citado 23/02/2024];114(3):247-52 Disponible en: http://www.actasdermo.org/es-pdf-S0001731022008948
Anasagasti-Angulo L, García-Vega Y, Barcelona-Pérez S, et al. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer [Internet]. 2009 [citado 23/11/2023];9:262. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724551/
Herrera-Porro JA, Castro-Cárdenas K, Iserm-Pérez BB. Serie de tres pacientes con carcinoma epidermoide periocular tratados con HeberFERON. Informe de caso. MediCiego [Internet]. 2021 [citado 23/11/2023];27:e1633 Disponible en: https://revmediciego.sld.cu/index.php/mediciego/article/view/1633/3721
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Médica Electrónica (Medical Electronic Journal)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.
It allows:
- Copy and redistribute published material in any medium or format.
- Adapt the content.
This will be done under the following terms:
- Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.
- Non-commercial use.
- Recognize the journal where it is published.
The copyrights of each article are maintained, without restrictions.
Guidelines to authors
